Konruns Pharmaceutical released its 2026 semi-annual report, achieving net profit attributable to shareholders of approximately 95.7226 million yuan in the first half, up 5.14% year on year. The company achieved operating revenue of approximately 463 million yuan in the same period, up 0.42% year on year. During the reporting period, research and development investment was approximately 64.9779 million yuan, up 29.03% year on year, accounting for 14.04% of operating revenue, with the development progress of core pipeline drug candidates continuing to advance rapidly. Konruns Pharmaceutical focuses on the research and development, production, and sales of innovative drugs.
Beijing Konruns Pharmaceutical Co LtdNet profit up 5.14% and revenue up 0.42%, with R&D investment up 29.03%.
